Literature DB >> 22571206

Lenalidomide in myeloma--a high-maintenance friend.

Ashraf Z Badros.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22571206     DOI： 10.1056/NEJMe1202819

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.

Authors:  S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2012-06-05       Impact factor: 66.675

2.  Minimal residual disease in multiple myeloma.

Authors:  Nikhil C Munshi; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

Review 3.  From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma.

Authors:  David S Siegel
Journal:  Ther Adv Hematol       Date:  2013-12

4.  Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.

Authors:  C Fernández de Larrea; R Jiménez; L Rosiñol; E Giné; N Tovar; M T Cibeira; F Fernández-Avilés; C Martínez; M Rovira; J Bladé
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

5.  Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.

Authors:  Sinto Sebastian; Yuan X Zhu; Esteban Braggio; Chang-Xin Shi; Sonali C Panchabhai; Scott A Van Wier; Greg J Ahmann; Marta Chesi; P Leif Bergsagel; A Keith Stewart; Rafael Fonseca
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

6.  Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.

Authors:  Brian L Burnette; Angela Dispenzieri; Shaji Kumar; Ann M Harris; Jeff A Sloan; Jon C Tilburt; Robert A Kyle; S Vincent Rajkumar
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

7.  Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.

Authors:  Joaquin Martinez-Lopez; Juan J Lahuerta; François Pepin; Marcos González; Santiago Barrio; Rosa Ayala; Noemí Puig; María A Montalban; Bruno Paiva; Li Weng; Cristina Jiménez; María Sopena; Martin Moorhead; Teresa Cedena; Immaculada Rapado; María Victoria Mateos; Laura Rosiñol; Albert Oriol; María J Blanchard; Rafael Martínez; Joan Bladé; Jesús San Miguel; Malek Faham; Ramón García-Sanz
Journal:  Blood       Date:  2014-03-19       Impact factor: 22.113

8.  Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.

Authors:  Ailing Liu; Shirong Li; Vera Donnenberg; Jing Fu; Susanne M Gollin; Huihui Ma; Caisheng Lu; Donna B Stolz; Markus Y Mapara; Sara A Monaghan; Suzanne Lentzsch
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

9.  Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.

Authors:  Hai-Ying Hua; Hua-Qiang Gao; Ai-Ning Sun; Jian-Nong Cen; Li-Li Wu
Journal:  Mol Med Rep       Date:  2016-09-26       Impact factor: 2.952
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.